Start your research on the Biotechnology and Pharmaceutical Industries with our collection of resources available through Yale University Library.
Researchers are responsible for ensuring that their use complies with the publishers' license agreements with Yale University.
Please refer to our polices on E-Resources Access and Use for more information.
To access library licensed resources use the Yale Secure wifi connection while on-campus.
Off Campus? Use VPN to access library resources.
Looking for even more business information?
Visit the Business & Management Research Guide.
Death to Beauty by
In the 1970s, Dr. Alan Scott sought to selectively weaken eye muscles to treat strabismus (when one or both eyes are misaligned) without surgery. After failed attempts with other agents, Scott developed a method to stabilize the bacteria that causes botulism, culminating in a drug that eventually became known as Botox. In Death to Beauty, Eugene M. Helveston, MD, follows the unlikely story of botulism's 1817 discovery in contaminated German sausages, to its use in military and research facilities, to Scott, an ophthalmologist who aimed to safely use the drug in humans. Scott struggled alone as an unknown in the pharmaceutical industry, searching for clinical trial financing and FDA approval, which he achieved at a fraction of the billions big pharma usually spends to bring a drug to market. Eventually, the company Allergan bought him out, capitalizing on the possibilities for cosmetic uses. Scott's formula was renamed "Botox" and reached annual sales in the billions. After the sale, Scott received no further compensation from Botox sales and remained the same unassuming man. A fascinating walk through the intricate history of how the world's deadliest toxin starting as a treatment for crossed eyes became a routine tool for the cosmetic industry, Death to Beauty will make you rethink success, beauty, and deadly bacteria.
Biopharmaceutical Manufacturing by
This volume "Cell Engineerring 11 - Biopharmaceutical Manufacturing: Progress, Trends and Challenges" is a source of the latest innovative research and technical development in biomanufacturing systems. It is organised into 2 parts: 1) Manufacturing of recombinant therapeutic proteins (e.g. therapeutic antibodies, biosimilars/biogenerics) and 2) Manufacturing aspects of cell and gene therapy. Each with selected chapters on the following topics for both up- and downstream, such as: Advanced process strategies, especially continuous manufacturing, Advanced culture techniques, especially single-use systems, Process transfer, scale-up/scale-down models, Processing advances/Manufacturing productivity/efficiency, Model-assisted process understanding and development/Digital Twins, Process controls and analytics, Quality control, Quality by design, Facility design and full-scale commercial systems, manufacturing technology innovation. The book comprises contributions of experts from academia and industry active in the field of cell culture development for the production of recombinant proteins, cell therapy and gene therapy, with consideration of Digital Twin´s and facility design. The knowledge and expertise of the authors cover disciplines like cell biology, engineering, biotechnology and biomedical sciences. Inevitably, some omissions will occur in the test, but the authors have sought to avoid duplications by extensive cross-referencing to chapters in other volumes of this series and elsewhere. We hope the volume provides a useful compendium of techniques for scientists in industrial and research laboratories active in this field.
Pharmanomics by
Investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences. Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financialising medicine--from Purdue's rapacious marketing of highly addictive OxyContin through Martin Shkreli's hiking the price of a lifesaving drug to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication. Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.
@YALELIBRARY
© 2022 Yale University Library • All Rights Reserved
